“We believe IDbyDNA’s technology has hit a tipping point and is now set to revolutionize the way we respond to, and tackle, infectious disease outbreaks, and address the growing concerns of antimicrobial resistance,” said Stuart Peterson, partner at Artis Ventures. “Having led their series A round, we have had a front row seat to the incredible insights that genomics and AI can deliver, and IDbyDNA’s approach to metagenomic testing presents a unique opportunity to improve pathogen identification and infectious disease diagnosis.”
Artis general partner Stuart Peterson said the firm was confident in its investment because of Crediwatch’s commitment to addressing the gaps in the digital lending space, adding that the firm was positioned to leverage the failure of conventional credit rating and underwriting methods through their technology. Crediwatch, which was founded in 2013, is a data insights-as-a-service company that provides businesses and lenders with credit intelligence that allows them to increase and improve their trading activity. It provides its solutions for financial institutions, enterprises as well as legal and private equity firms, according to its website.
